Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2025
0mins
Should l Buy ?
Source: Globenewswire
Norovirus Strain Update: Norovirus GII.17 variants have surpassed GII.4 as the leading strain, causing a significant rise in outbreaks across the U.S. and Europe in 2024-2025.
CDI-988 Development: Cocrystal Pharma's CDI-988, a pan-viral protease inhibitor, has shown promising antiviral activity against major norovirus strains and is set to enter human challenge studies in 2025 for potential treatment and prevention of infections.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
